Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
2015 · New England Journal of Medicine · 731 citations
https://doi.org/10.1056/nejmoa1406281
H
Hao Guo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
102
Papers
3.5K
Citations
24
h-index
37
i10-index
Hao Guo is an academic researcher from Central South University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies. The author has an h-index of 24, co-authored 87 publications.
ORCID: 0000-0003-1658-0989Papers by this author
worksSeven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2019 · Journal of Clinical Oncology · 276 citations
https://doi.org/10.1200/jco.19.00066
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
2018 · npj Breast Cancer · 142 citations
https://doi.org/10.1038/s41523-018-0060-z
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
2020 · Breast Cancer Research · 141 citations
https://doi.org/10.1186/s13058-020-01354-y
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
2015 · JAMA Oncology · 91 citations
https://doi.org/10.1001/jamaoncol.2015.3709
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity
2019 · JACC Heart Failure · 51 citations
https://doi.org/10.1016/j.jchf.2019.04.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat